Association between the IVS4G>T mutation in the TCF7L2 gene and susceptibility to diabetes in cystic fibrosis patients

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Furgeri, Daniela Tenório ^a   Marson, Fernando Augusto De Lima ^a   Ribeiro, Antonio Fernando ^a   Bertuzzo, Carmen Silvia ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Cystic fibrosis; Diabetes; IVS4G>T; rs12255372; TCF7L2

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; TCF7L2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR 7 LIKE 2;

ARTICLE; BRAZIL; CHILD; COMORBIDITY; CYSTIC FIBROSIS; DIABETES MELLITUS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; MALE; MUTATION; SINGLE NUCLEOTIDE POLYMORPHISM;

BRAZIL; CHILD; COMORBIDITY; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DIABETES MELLITUS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSCRIPTION FACTOR 7-LIKE 2 PROTEIN;

EID: 84871012874     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-561     Document Type: Article

References (11)

1. Qualitative and quantitative analysis of mRNA associated with four putative splicing mutations (621+3A->G, 2751+2T->A, 296+1G->C, 1717-9T->C-D565G) and one nonsense mutation (E822X) in the CFTR gene. Tzetis M, Efthymiadou A, Doudounakis S, Kanavakis E, Hum Genet 2001 109 6 592 601 10.1007/s00439-001-0631-0 11810271
2. Cystic Fibrosis Genetic Analysis Consortium-CFGAC, Disponível em: http://www.genet.sickkids.on.ca/cftr. Accessed November 22, 2012
3. Cystic fibrosis and survival to 40 years: a case-control study. Simmonds NJ, MacNeil SJ, Cullinan P, Hodson ME, Eur Respir J 2010 36 6 1277 1283 10.1183/09031936.00001710 20378603
4. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Moran A, Hardin D, Rodman D, Allen HF, Beall RJ, Borowitz D, Brunzell C, Campbell PW, Chesrown SE, Duchow C, Fink RJ, Fitzsimmons SC, Hamilton N, Hirsch I, Howenstine MS, Klein DJ, Madhun Z, Pencharz PB, Quittner AL, Robbins MK, Schindler T, Schissel K, Schwarzenberg SJ, Stallings VA, Zipf WB, Diabetes Res Clin Pract 1999 45 61 73 10.1016/S0168-8227(99)00058-3 10499886
5. Cystic fibrosis-related diabetes. Mackie AD, Thornton SJ, Edenborough FP, Diabet Med 2003 20 425 436 10.1046/j.1464-5491.2003.00924.x 12786675
6. A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Blackman SM, Hsu S, Ritter SE, Naughton KM, Wright FA, Drumm ML, Knowles MR, Cutting GR, Diabetologia 2009 52 9 1858 1865 10.1007/s00125-009-1436-2 19585101
7. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Milla CE, Warwick WJ, Moran A, Am J Respir Crit Care Med 2000 162 891 895 10988101
8. Long-term effect of insulin treatment in cystic fibrosis-related diabetes. Mohan K, Israel KL, Miller H, Grainger R, Ledson MJ, Walshaw MJ, Respiration 2008 76 181 186 10.1159/000110206 17960051
9. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, Saydah SH, Williams DE, Geiss LS, Gregg EW, Diabetes Care 2006 29 1263 1268 10.2337/dc06-0062 16732006
10. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadottir A, Styrkarsdottir U, Magnusson KP, Walters GB, Palsdottir E, Jonsdottir T, Gudmundsdottir T, Gylfason A, Saemundsdottir J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G, Thorsteinsdottir U, Gulcher JR, Kong A, Stefansson K, Nat Genet 2006 38 320 323 10.1038/ng1732 16415884
11. Diabetes Prevention Program Research Group. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR, Knowler WC, Nathan DM, Altshuler D, N Engl J Med 2006 355 3 241 250 10.1056/NEJMoa062418 16855264